
Management of Follicular Lymphoma Lymphoma Tumor Board September 22, 2017

Relative Incidence of NHL Subtypes

>71,000 new cases in US in 2015



NHL – non-Hodgkin lymphoma; FL – follicular lymphoma; DLBCL – diffuse large B-cell lymphoma. Armitage & Weissenburger, 1998; ACS, 2015.



Printed by Andrea Towlerton on 3/30/2017 6:37:06 PM. For personal use only. Not approved for distribution. Copyright @ 2017 National Comprehensive Cancer Network, Inc., All Rights Reserved.

NCCN NCCN NCCN Network[®]

NCCN Guidelines Version 3.2017 Table of Contents B-cell Lymphomas

NCCN Guidelines Index Table of Contents Discussion

NCCN B-cell Lymphoma Panel Members Summary of the Guidelines Updates

- Follicular Lymphoma (FOLL-1)
- Marginal Zone Lymphomas (MZL-1)
- Gastric MALT Lymphoma (MALT-1)
- Nongastric MALT Lymphoma (NGMLT-1)
- Nodal Marginal Zone Lymphoma (NODE-1)
- Splenic Marginal Zone Lymphoma (SPLN-1)
- Mantle Cell Lymphoma (MANT-1)
- Diffuse Large B-Cell Lymphoma (BCEL-1)
- Burkitt Lymphoma (BURK-1)
- <u>AIDS-Related B-Cell Lymphomas (AIDS-1)</u>
- Lymphoblastic Lymphoma (BLAST-1)
- Post-Transplant Lymphoproliferative Disorders (PTLD-1)
- Castleman's Disease (CD-1)
- <u>Use of Immunophenotyping/Genetic Testing in Differential Diagnosis of Mature</u> <u>B-Cell and NK/T-Cell Neoplasms (NHODG-A)</u>
- Supportive Care for B-cell Lymphomas (NHODG-B)
- Lugano Response Criteria for Non-Hodgkin's Lymphoma (NHODG-C)
- Principles of Radiation Therapy (NHODG-D)
- <u>Special Considerations for the Use of Small-Molecule Inhibitors</u> (Ibrutinib and Idelalisib) (NHODG-E)

Primary CNS Lymphoma (See NCCN Guidelines for CNS) Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma (See NCCN Guidelines for WM/LPL)

The NCCN Guidelines[®] are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network[®] (NCCN[®]) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network[®]. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2017.

Version 3.2017, 03/27/17 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, <u>click here:</u> <u>nccn.org/clinical_trials/physician.html</u>.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified.


See <u>NCCN Categories of Evidence</u> and Consensus.

Classification and Staging (ST-1)


Indolent Non-Hodgkin Lymphomas

- Slow-growing [typically] B-cell malignancies
- Responsive to initial therapy, yet inevitably recur; incurable with conventional therapy
- Most common subtypes:
 - Follicular lymphoma (FL)
 - Marginal zone lymphoma (MZL)
 - Small lymphocytic lymphoma (SLL) CLL counterpart
- FL is the 2nd most common subtype of NHL
- FL comprises ~25% of NHL and ~70% of indolent NHL
- FL is a malignancy of follicle center B-cells CD10⁺
- Also known as CB/CC lymphoma (Centroblastic/Centrocytic lymphoma), nodular lymphoma, and Brill-Symmers Disease
- Hallmark translocation between chromosomes 14 and 18 [t(14;18)] that results in overexpression of *BCL2*

t(14;18) – Cytogenetic hallmark of FL



Model of FL pathogenesis




Brad S. Kahl, and David T. Yang Blood 2016;127:2055-2063

🛯 blood

Pathology of FL (1)

Follicular lymphoma-bone marrow biopsy - 1.

The arrow marks clusters of small lymphocytes (H&E). The paratrabecular distribution of involvement is a classic finding for follicular lymphoma.






Pathology of FL (2)

Follicular Lymphoma - 2.

Medium power showing back to back neoplastic follicles which have "lost" normal mantle zones.




Grading of FL

- According to WHO criteria, FL is morphologically graded into:
 - grade 1 (<5 centroblasts per highpower field (hpf))
 - grade 2 (6–15 centroblasts/hpf)
 - grade 3 (>15 centroblasts/hpf)
- Grade 3 is further subdivided into:
 - grade 3A (centrocytes still present)
 - grade 3B (the follicles consist almost entirely of centroblasts)
- The WHO 2008 update now classifies grades 1 and 2 as low grade follicular lymphoma, grade 3A as high grade follicular lymphoma, and grade 3B as Diffuse Large B Cell Lymphoma (DLBCL).
- Other factors to consider: Extranodal involvement:
 - Bone marrow
 - Peripheral Blood
 - Spleen
 - Liver

Low Power (Architectural)				
Benign	Malignant			
 Loosely packed follicles Polymorphic follicles Prominent mantle zones Polarized follicles Preserved open sinuses No capsular invasion or transgression Polyclonal light chain expression Non-reactive for BCL-2 	 Tightly packed follicles Monomorphic follicles Absent or obscured mantle zones Unpolarized follicles Destroyed and constricted sinuses Extension into perinodal soft tissue Monoclonal light chain expression Reactive for BCL-2 			
High Power (Cytological)				
Benign	Malignant			
 A very high mitotic rate Tingible-body macrophages Between follicles are the usual paracortical lymphoid cells 	 A lower mitotic rate No tingible-body macrophages Between follicles atypical cleaved cells may be found 			


Influence of the tumor microenvironment on FL



Brad S. Kahl, and David T. Yang <u>Blood</u> 2016;127:2055-2063



Representative tissue microarray cores of follicular lymphoma stained for FOXP3





Pedro Farinha et al. Blood 2010;115:289-295

Prevalence of HIV infection in US lymphoma patients in the HAART era

179,520 patients with lymphoma from the US National Cancer Database, 2004-2009:

- Follicular lymphoma: 1.0%
- Peripheral T-cell lymphoma: 3.3%
- Hodgkin lymphoma: 4.7%
- Diffuse large B cell lymphoma: 5.4%
- Burkitt lymphoma: 29.0%

Han et al., Cancer Epidemiol Biomarkers Prev March 1 2017 (26) (3) 303-311; DOI: 10.1158/1055-9965.EPI-16-0595

A model for the histogenesis of HIV-associated lymphomas showing molecular and viral pathogenesis and DLBCL taxonomy

Germinal Center Germinal Center B-cell type (GCB)	Post-Germinal CenterActivated B-cell type (ABC)Plasmacytic type		
Mild immunodeficiency	Severe immunodeficiency		
Moderate CD4 count	Low CD4 count		
Good Prognosis	Poor prognosis		
Post-CART	Pre-CART		
BL DLBCL-CB CD20 + CD20 + EBV +/- EBV -/+ MUM1/IRF4 - MUM1/IRF4. CD10/BCL6 + CD10/BCL6 +	DLBCL-IBPELPBCD20 +CD20-CD20-EBV ++/-EBV +EBV +MUM1/IRF4 +KSHV/HHV8 +KSHV/HHV8 +CD10/BCL6 -MUM1/IRF4 -MUM1/IRF4 -CD10/BCL6 -CD10/BCL6 -CD10/BCL6 -		

Kieron Dunleavy, and Wyndham H. Wilson Blood 2012;119:3245-3255



Printed by Andrea Towlerton on 3/30/2017 6:37:06 PM. For personal use only. Not approved for distribution. Copyright © 2017 National Comprehensive Cancer Network, Inc., All Rights Reserved.

Comprehensive NCCN Guidelines Version 3.2017 Follicular Lymphoma (grade 1-2)

NCCN Guidelines Index **Table of Contents** Discussion

GELF CRITERIA^{a,b}

- Involvement of ≥3 nodal sites, each with a diameter of ≥3 cm
- Any nodal or extranodal tumor mass with a diameter of ≥7 cm
- B symptoms

NCCN

Splenomegaly


National

Cancer

Network[®]

- · Pleural effusions or peritoneal ascites
- Cytopenias (leukocytes <1.0 x 10⁹/L and/or platelets <100 x 10⁹/L)
- Leukemia (>5.0 x 10⁹/L malignant cells)

FLIPI - 1 CRITERIA^{a,c,d} Age ≥60 y Ann Arbor stage III–IV Hemoglobin level <12 a/dL Serum LDH level >ULN (upper limit of normal) Number of nodal sites^d ≥5 **Risk group according to FLIPI chart** Number of factors Low 0 - 1Intermediate 2 ≥3 High



Manneguin used for counting the number of involved areas.^e

© 2007 Dana-Farber Cancer Institute, Inc.

All rights reserved. Permission is hereby granted for copying this image by photocopy or similar process for use in the practice of medicine or for research purposes. No other use is permitted which will infringe the copyright without the express written consent of Dana-Farber Cancer Institute, Inc.

- ^cThis research was originally published in Blood. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265. (c) the American Society of Hematology.
- dFLIPI-2 (Federico M, Bellei M, Marcheselli L, et al. J Clin Oncol 2009;27:4555-4562) predicts for outcomes after active therapy; see Discussion.
- ^eThe map is used to determine the number of nodal sites in FLIPI-1 criteria and is different than the conventional Ann Arbor site map.

^aThis provides useful prognostic information that may be used to guide therapeutic decisions.


^bSolal-Celigny P. Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa 2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaire 86 trial. J Clin Oncol 1998;16:2332-2338.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Version 3.2017, 03/27/17 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.

FOLL-A

An algorithmic approach to management of FL



Brad S. Kahl, and David T. Yang Blood 2016;127:2055-2063



Printed by Andrea Towlerton on 3/30/2017 6:37:06 PM. For personal use only. Not approved for distribution. Copyright © 2017 National Comprehensive Cancer Network, Inc., All Rights Reserved.



NCCN Guidelines Version 3.2017 Follicular Lymphoma (grade 1-2)

NCCN Guidelines Index Table of Contents Discussion

SUGGESTED TREATMENT REGIMENS^{a,b} (in preference order)

First-line Therapy

- Bendamustine + rituximab (category 1)
- Bendamustine + obinutuzumab^c
- RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) (category 1)
- CHOP + obinutuzumab^c
- RCVP (rituximab, cyclophosphamide, vincristine, prednisone) (category 1)
- CVP + obinutuzumab^c
- Rituximab (375 mg/m² weekly for 4 doses) (consider for low tumor burden)^d
- Lenalidomide + rituximab (category 2B)

<u>First-line Therapy for Elderly or Infirm</u> (if none of the above are expected to be tolerable in the opinion of treating physician)

- Rituximab (preferred) (375 mg/m² weekly for 4 doses)
- Single-agent alkylators (eg, chlorambucil or cyclophosphamide) ±
 rituximab
- Radioimmunotherapy^{e,f} (category 2B)

^aSee references for regimens FOLL-B 3 of 4 and FOLL-B 4 of 4.

- ^bThe choice of initial therapy requires consideration of many factors, including age, comorbidities, and future treatment possibilities (eg, HDT with SCR). Therefore, treatment selection is highly individualized.
- ^CThe clinical trial evaluating this regimen included obinutuzumab maintenance. The use without maintenance was an extrapolation of the data.
- ^dRituximab may be appropriate in patients initially observed and with progression of low tumor burden disease not meeting GELF criteria (<u>FOLL-A</u>). Immediate initial therapy with rituximab in patients not meeting GELF criteria has not improved OS (Ardeshna K, et al. Lancet Oncol 2014;15:424-435).
- ^eSelection of patients requires adequate marrow cellularity >15% and <25% involvement of lymphoma in bone marrow, and platelets >100,000. In patients with prior autologous stem cell rescue, referral to a tertiary care center is highly recommended for radioimmunotherapy.

First-line Consolidation or Extended Dosing (optional)

- Rituximab maintenance 375 mg/m² one dose every 8 wks for 12 doses for patients initially presenting with high tumor burden (category 1)^g
- Obinutuzumab maintenance (1000 mg every 8 weeks for 12 doses)
- If initially treated with single-agent rituximab, consolidation with rituximab 375 mg/m² one dose every 8 weeks for 4 doses
- Radioimmunotherapy (after induction with chemotherapy or chemoimmunotherapy)^{e,f,h} (category 2B)

See Second-line and Subsequent Therapy on FOLL-B 2 of 4

Consider prophylaxis for tumor lysis syndrome (<u>See NHODG-B</u>) See monoclonal antibody and viral reactivation (<u>NHODG-B</u>)

- ^fIf radioimmunotherapy is considered, bilateral cores are recommended and the pathologist should provide the percent of overall cellular elements and the percent of cellular elements involved in the marrow. Cytogenetics ± FISH for known MDS markers. As of 2010, updates suggest a trend towards an increased risk of MDS with RIT.
- ⁹This is based on the PRIMA study for patients with high tumor burden treatment with RCVP and RCHOP. There are no data following other regimens.
- ^hThe full impact of an induction regimen containing rituximab on RIT consolidation is unknown.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

BR vs R-CHOP Non-Heme Toxicities


	B-R (n=261)	R-CHOP (n=253)	p value
Alopecia	0	245 (100%)*	<0.0001
Paresthesia	18 (7%)	73 (29%)	<0.0001
Stomatitis	16 (6%)	47 (19%)	<0.0001
Skin (erythema)	42 (16%)	23 (9%)	0.024
Skin (allergic reaction)	40 (15%)	15 (6%)	0.0006
Infectious episodes	96 (37%)	127 (50%)	0.0025
Sepsis	1 (<1%)	8 (3%)	0.019


B-R=bendamustine plus rituximab. R-CHOP=CHOP plus rituximab. *Includes only patients who received three or more cycles.

Histologic transformation of FL

- Histologic transformation: a biologic event leading to the development of a high-grade, aggressive non-Hodgkin lymphoma in patients with an underlying follicular lymphoma (FL).
- Transformation to diffuse large B-cell lymphoma (DLBCL) or Burkitt lymphoma is also known to take place in other subtypes of indolent lymphoma such as marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia (Richter's syndrome), and lymphocyte predominant Hodgkin lymphoma, but is best described as occurring in FL.
- Survival after transformation has historically been poor, but has improved in the rituximab era.

Mutational analyses of FL clonal architecture yields insights into histologic transformation








Pedro Farinha et al. Blood 2010;115:289-295


Overall survival curve based on FOXP3 immunoarchitectural patterns






Pedro Farinha et al. <u>Blood</u> 2010;115:289-295

Approach to treatment of transformed FL




Post transformation survival for confirmed and suspected histologic transformation of FL



Nina D. Wagner-Johnston et al. <u>Blood</u> 2015;126:851-857



Survival curves of HIV⁺ individuals with lymphoma



Han et al., Cancer Epidemiol Biomarkers Prev March 1 2017 (26) (3) 303-311; DOI: 10.1158/1055-9965.EPI-16-0595

References

- Casulo, C., Burack, W. R., & Friedberg, J. W. (2015). Transformed follicular non-Hodgkin lymphoma. Blood, 125(1), 40-47. Accessed March 29, 2017. <u>https://doi.org/10.1182/blood-2014-04-516815</u>.
- Kahl, B. S., & Yang, D. T. (2016). Follicular lymphoma: evolving therapeutic strategies. Blood, 127(17), 2055-2063. Accessed March 29, 2017. https://doi.org/10.1182/blood-2015-11-624288.
- Monsalvez, V., Montes-Moreno, S., Artiga, M. J., Rodriguez, M. E., Espiridion, B. S., Lozano, M., . . . Ortiz-Romero, P. L. (2013). MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. *Mod Pathol, 26*(4), 617. doi:10.1038/modpathol.2012.209
- Nastoupil, L. J., McLaughlin, P., Feng, L., Neelapu, S. S., Samaniego, F., Hagemeister, F. B., . . . Fowler, N. H. (2017). High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. *Br J Haematol*. doi:10.1111/bjh.14541
- Farinha, P., Al-Tourah, A., Gill, K., Klasa, R., Connors, J. M., & Gascoyne, R. D. (2010). The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood, 115(2), 289-295. Accessed September 20, 2017. https://doi.org/10.1182/blood-2009-07-235598.
- Dunleavy, K., & Wilson, W. H. (2012). How I treat HIV-associated lymphoma. Blood, 119(14), 3245-3255. Accessed September 19, 2017. <u>https://doi.org/10.1182/blood-2011-08-373738</u>.
- Dolcetti, R., Gloghini, A., Caruso, A., & Carbone, A. (2016). A lymphomagenic role for HIV beyond immune suppression?. Blood, 127(11), 1403-1409. Accessed September 19, 2017. <u>https://doi.org/10.1182/blood-2015-11-681411</u>.
- Han X, Jemal A, Hulland E, Simard EP, Nastoupil L, Ward E, et al. HIV Infection and Survival of Lymphoma Patients in the Era of Highly Active Antiretroviral Therapy. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2017;26(3):303-11.
- <u>http://imagebank.hematology.org/</u>
- http://www.pathpedia.com/education/eatlas/histopathology/bone_marrow/waldenstrom_macroglobulinemia.aspx
- https://en.wikipedia.org/wiki/Follicular_lymphoma
- https://lymphomanewstoday.com/2017/01/10/follicular-lymphoma-can-develop-along-two-paths/
- https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#b-cell
- <u>http://pleiad.umdnj.edu/hemepath/follicular/follicular.html</u>
- http://www.thesmallbusinesssite.co.za/wp-content/uploads/2016/07/medical-730x495.jpg